CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
about
Deep sequencing of MYC DNA-binding sites in Burkitt lymphomaProteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.RIP1 expression is necessary for CD30-mediated cell death induction in anaplastic large-cell lymphoma cells.TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Molecular genetics of peripheral T-cell lymphomas.Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells.Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma.Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs.Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.CD30+ lymphoproliferative disordersUnderstanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.Brentuximab vedotin: clinical updates and practical guidance.
P2860
Q28742928-0E2F5010-5593-4C44-B595-14DE8B0B4352Q33507899-D093E7D3-D974-45BA-B905-819FD76333BCQ34643604-033D3C7E-4662-4A45-96F1-C55121ADBE72Q35125212-6B71BB0C-E31B-489E-8877-81CFD42DA8CCQ35607281-7611718C-0B4E-441D-B0EC-22C84407D239Q37149264-0CED9030-FA90-4AD5-9EF0-D818FB914963Q37372827-52F04465-B56C-4E5F-8BD4-1CF972FE9219Q37577541-9AD7B994-1FB8-4C13-9B89-C410929FF73DQ37962701-0FF7E52C-C454-4DAA-A7DF-E22A42BC5906Q38164572-65EDD131-FE17-4C97-8F92-51BCB325E66BQ38183757-AE473510-D3BF-47D8-9D42-AB047AFB119AQ38331230-32FADDAD-8E1F-42F1-B229-F3B0B52AC39DQ39106578-FEC98AD5-7AF8-4EE3-944D-67DC10B25218Q39468269-C825E675-6233-4DEC-B517-AB2698CC3E66Q39615506-14FB5F3E-2800-4083-826C-0E10530F05A8Q41447830-7D992396-AA08-4B34-8C24-82BE2ADF78AAQ42091712-67C19803-E7D9-412C-B1B4-EF7465CF6ECDQ42277563-3F1E3BCD-0CD7-4C3D-9D5F-18F4EB0C33D4Q42415931-0C72CFC8-3FF0-46AA-AE20-7AB3D58C33B2Q47102763-68899327-165F-48F2-9716-3C457BCAB7C9Q49282959-46B31397-9F2B-4CCE-8862-C80092BC9C22
P2860
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
CD30-induced signaling is abse ...... tic large cell lymphoma cells.
@en
type
label
CD30-induced signaling is abse ...... tic large cell lymphoma cells.
@en
prefLabel
CD30-induced signaling is abse ...... tic large cell lymphoma cells.
@en
P2093
P2860
P1476
CD30-induced signaling is abse ...... tic large cell lymphoma cells.
@en
P2093
Burkhard Hirsch
Fariba Fouladi
Harald Stein
Horst Dürkop
Rainer Spang
Raphael Zollinger
Stefan Bentink
P2860
P304
P356
10.2353/AJPATH.2008.070858
P407
P577
2008-01-10T00:00:00Z